ReviewF1000Research2020
Drug Therapies for the Management of Sickle Cell Disease.
Review in F1000Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Pooled it
- Beyond hematopoietic stem cell transplantation: positioning Africa for scalable uptake of innovative sickle cell therapies.BMJ global health · 2026Article
- Impact of sickle cell anaemia on reproductive health: a narrative review.Reproductive health · 2025Review
- Hospital Readmissions Among People With Sickle Cell Disease.JAMA network open · 2025Article
- Burden of hemoglobinopathies and hemolytic anemias in the World Health Organization African region, 2000-2021: Findings from the Global Burden of Disease 2021 study.PLOS global public health · 2025Article
- The Prevalence and Correlates of Aberrant Opioid-Related Behaviours among Patients with Sickle Cell Disease in Oman:Sultan Qaboos University medical journal · 2025Article
- Clinical Insights into Sickle Cell Disease: A Comprehensive Multicenter Retrospective Analysis of Clinical Characteristics and Outcomes Across Different Age Groups.Journal of clinical medicine · 2024Article
- Using disease-modifying therapies in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2023Article
- Review
- Review
- Barriers to medication adherence in sickle cell disease: A comprehensive theory-based evaluation using the COM-B model.Pediatric blood & cancer · 2023Article
- Article
- Treatment of sickle cell disease - options and perspective.American journal of blood research · 2023Review
- Effective therapies for sickle cell disease: are we there yet?Trends in genetics : TIG · 2022Review
- The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.BMC emergency medicine · 2022Article
- Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence.Acta bio-medica : Atenei Parmensis · 2022Review
- Recent advances in "sickle and niche" research - Tribute to Dr. Paul S Frenette.Stem cell reports · 2022Review
- Review
- Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria.PloS one · 2022Article
- Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome.Journal of blood medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Sickle cell disease (SCD) afflicts millions of people worldwide but is referred to as an orphan disease in the United States. Over the past several decades, there has been an increasing understanding of the pathophysiology of SCD and its complications. While most individuals with SCD in resource-rich countries survive into adulthood, the life expectancy of patients with SCD remains substantially shorter than for the general African-American population. SCD can be cured using hematopoietic stem cell transplantation and possibly gene therapy, but these treatment approaches are not available to most patients, the majority of whom reside in low- and middle-income countries. Until relatively recently, only one drug, hydroxyurea, was approved by the US Food and Drug Administration to ameliorate disease severity. Multiple other drugs (L-glutamine, crizanlizumab, and voxelotor) have recently been approved for the treatment of SCD, with several others at various stages of clinical testing. The availability of multiple agents to treat SCD raises questions related to the choice of appropriate drug therapy, combination of multiple agents, and affordability of recently approved products. The enthusiasm for new drug development provides opportunities to involve patients in low- and middle-income nations in the testing of potentially disease-modifying therapies and has the potential to contribute to capacity building in these environments. Demonstration that these agents, alone or in combination, can prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.